Core Viewpoint - Shanghai Pharmaceuticals Group Co., Ltd. announced a cash dividend distribution of 0.12 RMB per share for the first half of 2025, approved at the second extraordinary general meeting of shareholders on December 9, 2025 [2][3]. Distribution Plan - The distribution is based on a total share capital of 3,708,361,809 shares, with A-shares accounting for 2,789,289,105 shares, resulting in a total cash dividend payout of approximately 445 million RMB, of which about 335 million RMB is allocated to A-share dividends [4]. - The cash dividend will be distributed to all A-share shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the day before the dividend record date [3][4]. Implementation Details - The cash dividends for A-shares will be distributed through the clearing system of China Securities Depository and Clearing Corporation Limited, with shareholders who have designated trading able to receive their dividends on the payment date [5]. - For shareholders without designated trading, the dividends will be held by China Securities Depository and Clearing Corporation Limited until they complete the necessary trading arrangements [5]. Taxation Information - For individual shareholders holding unrestricted A-shares, the tax treatment varies based on the holding period, with a maximum tax rate of 20% for shares held for one month or less, and a reduced rate of 10% for shares held between one month and one year [9]. - For institutional investors classified as resident enterprises under the Corporate Income Tax Law, they are responsible for their own tax payments, with the actual cash dividend remaining at 0.12 RMB per share [10]. - Qualified Foreign Institutional Investors (QFIIs) will have a withholding tax of 10% applied to their dividends, with provisions for tax treaty benefits available [11].

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司 2025 年半年度權益分派實施公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 12 月 25 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称：上海医 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-118 上海医药集团股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.12元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/12/31 | － | 2026/1/5 | 2026/1/5 | 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 12 月 9 日的2025年第二次临时股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体 A 股股东。 H 股 股 东 的 现 金 分 红 有 关 情 况 详 见 本 公 司 在 香 港 联 合 交 易 所 有 限 公 司 网 ...

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of its 2025 interim profit distribution plan at the second extraordinary general meeting of shareholders in 2025, indicating a commitment to returning value to shareholders through cash dividends [1] Summary by Categories Profit Distribution - The profit distribution is based on a total share capital of 3.708 billion shares, with a cash dividend of 0.12 yuan per share (before tax), totaling 445 million yuan in cash dividends [1] - Among the total cash dividends, 335 million yuan will be distributed to A-shares [1] Key Dates - The A-share registration date is set for December 31, 2025, while the ex-dividend date and cash dividend payment date are scheduled for January 5, 2026 [1] Dividend Distribution Mechanism - The cash dividends for A-shares held by Shanghai Pharmaceuticals Group and three other companies will be distributed directly by the company, while the remaining A-share dividends will be entrusted to China Securities Depository and Clearing Corporation Limited Shanghai Branch for distribution [1]

Group 1 - The core point of the article is the establishment of a new company, Shanghai Pharmaceutical Smart Supply Chain Technology Co., Ltd., which is fully owned by Shanghai Pharmaceuticals [1] - The legal representative of the new company is Ren Gang, and it has a registered capital of 20 million yuan [1] - The business scope of the company includes intelligent control system integration, artificial intelligence application software development, AI industry application system integration services, and supply chain management services [1]

Core Viewpoint - The announcement details the third exercise period for the stock option incentive plan of Shanghai Pharmaceuticals, specifying the dates and restrictions for exercising the options [1][2]. Group 1: Stock Option Plan Details - The third exercise period for the reserved stock options will commence on February 8, 2025, and conclude on February 7, 2026 [1]. - The restriction period for exercising the stock options is set from December 22, 2025, to January 5, 2026, during which all incentive recipients will be restricted from exercising their options [1]. Group 2: Compliance and Administration - The company will apply to the China Securities Depository and Clearing Corporation Limited Shanghai Branch for handling matters related to the exercise restrictions in accordance with relevant regulations [2].

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該 等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站 (http://www.sse.com.cn)刊登的《上海醫藥集團股份有限公司關於 2019 年 A 股股 票期權激勵計劃預留股票期權第三個行權期限制行權期間的提示性公告》僅供參 閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 12 月 19 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称：上海医药 编号：临 2025-1 ...

一、预留股票期权第三个行权期自2025年2月8日起至2026年2月7日止。 二、本次限制行权期为2025年12月22日至2026年1月5日，在此期间全部激励 对象将限制行权。 证券代码：601607 证券简称：上海医药 编号：临 2025-117 上海医药集团股份有限公司 关于 2019 年 A 股股票期权激励计划 预留股票期权第三个行权期限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上市公司股权激励管理办法》、《上海证券交易所上市公司自律监管 指南第2号—业务办理》、《上海医药集团股份有限公司2019年股票期权激励计 划》及中国证券登记结算有限责任公司上海分公司（以下简称"中证登上海分公 司"）关于股票期权自主行权的相关规定，并结合上海医药集团股份有限公司（以 下简称"公司"）2025半年度权益分派计划，现对公司2019年股票期权激励计划 预留股票期权第三个行权期限制行权期间（以下简称"本次限制行权期"）公告 如下： 三、公司将按照有关规定及时向中证登上海分公司申请办理限制行权相关事 ...

Core Viewpoint - Shanghai Pharmaceuticals has received approval for its innovative drug, Suojirolin, aimed at treating primary hypertension, marking a significant achievement in its commitment to independent innovation in the pharmaceutical industry [1][2]. Group 1: Product Approval and Clinical Significance - The National Medical Products Administration (NMPA) has officially approved Suojirolin (brand name: Xintuoan), a first-class innovative drug for the treatment of primary hypertension [1]. - Suojirolin is a new generation of oral non-peptide small molecule renin inhibitors, designed to meet unmet clinical needs, providing a new treatment option for over 300 million patients with primary hypertension in China [1]. - Clinical trials have shown that Suojirolin demonstrates good efficacy and safety, with its Phase II trial results published in the authoritative journal "Hypertension Research," indicating growing global academic interest in Chinese innovative drugs [1]. Group 2: Research and Development Strategy - Shanghai Pharmaceuticals has positioned research and development (R&D) innovation at its strategic core, with a planned R&D investment of 2.818 billion yuan for 2024, leading the industry in investment intensity [2]. - As of the end of Q3 2025, the company has submitted 57 new drug applications for clinical trials, including 45 innovative drug pipelines, establishing a comprehensive and tiered R&D team [2]. - The company has several innovative drugs in advanced clinical stages, including a CD20 injection for neuromyelitis optica and a traditional Chinese medicine for cervical spondylosis, indicating a robust pipeline [2]. Group 3: Collaborative Innovation and Market Strategy - Shanghai Pharmaceuticals has established the Shanghai Frontier Biomedical Innovation Center to foster an open innovation ecosystem by collaborating with top universities and research institutions [3]. - The company has created a comprehensive distribution network covering over 80,000 medical institutions across 25 provinces and municipalities in China, ensuring effective market access for Suojirolin [3]. - The integration of online and offline pharmaceutical services enhances the company's ability to reach patients quickly and efficiently [3].

Core Viewpoint - Shanghai Pharmaceuticals has received approval for its Hydroxychloroquine Sulfate Tablets from the Philippines Food and Drug Administration, allowing the product to be marketed [1] Group 1 - The product is manufactured by Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals [1] - The approval signifies a potential expansion of the company's market presence in the pharmaceutical sector [1]